FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* LEE WILLIS C			2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner						
(Last) (First) (Middle) 21250 HAWTHORNE BLVD., SUITE 800			3. Date of Earliest Transaction (Month/Day/Year) 05/26/2021								X Officer (give title below) Other (specify below) Vice Chairman & COO						
TORRANCE, CA 90503			4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
e)	(Zip)		Table I - No				on-Derivative Securities Acqu			cquir	lired, Disposed of, or Beneficially Owned						
Instr. 3) Date (Month/Day/Year)		Execution Date, if any		if Co	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)) Be Re	Reported Transaction(s)			Form:		7. Nature of Indirect Beneficial Ownership	
		(Code	V	Amount	(A) or (D)			ilisti. 3 anu 4)			or Ind (I)	irect (I		
oar 05/26	5/2021				P		2,700	A	\$ 1.53 (1)	24	14,774			D			
oar 05/27	7/2021				P		2,000		\$ 1.58 (2)	24	16,774			D			
oar 05/28	3/2021				P		3,900		\$ 1.57 (3)	25	50,674			D			
oar										10	08,761			I	Fi Ti IF W	delity raditional A FBO fillis C.	
e line for each	class of secu	ırities ber	neficially	own	ed dire	ctly c	or indirectl	ly.									
			•			СО	ntained i	n this	form	are i	not requ	ired to res	pond ur	nless	SEC	1474 (9-02)	
											Owned						
Title of 2. 3. Transaction 2A. Deemed Execution Date (Month/Day/Year) any		ate, if T	, if Transaction Number of		6. an (M	. Date Exercisable nd Expiration Date Month/Day/Year) 7. Ar Ur Se		7. Titl Amou Under Secur (Instr.	Eitle and count of derlying curities str. 3 and Security (Instr. 5) 8. Price of Derivative Security (Instr. 5) 9. Numb Derivative Securities Gecurities Henefici Owned Following Reported Transact		over Ownership Solution Soluti		(Instr. 4)				
									tion 7	Title							
	Dar 05/26 Dar 05/26 Dar 05/26 Dar 05/28 Dar unsaction	(Middle) BLVD., SUITE 800 at (Zip) 2. Transaction Date (Month/Day/Year) Dar 05/26/2021 Dar 05/28/2021 Dar 05/28/2021 Dar 05/28/2021 Table II - ansaction 3A. Deemed Execution Date (Month/Day/Year) ansaction 3A. Deemed Execution Date (Month/Day/Year)	Emm 3. Date (Middle) 3. Date (05/26) 4. If A 3. December of the property	Emmaus Life 3. Date of Earli 05/26/2021 4. If Amendme 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Execution Date, if Darr 05/26/2021 Darr 05/28/2021 Table II - Derivative Secutes, puts, calls, ansaction 3. Deemed Execution Date, if Transaction 3. Date of Earli 05/26/2021	Emmaus Life Sci 3. Date of Earliest To 05/26/2021 4. If Amendment, Date of Earliest To 05/26/2021 4. If Amendment, Date of Earliest To 05/26/2021 2. Transaction Date of Execution Date, if any (Month/Day/Year) Dar 05/26/2021 Dar 05/27/2021 Dar 05/28/2021 Dar 05/28/2021	Emmaus Life Sciences 3. Date of Earliest Transact 05/26/2021 4. If Amendment, Date Original Sciences 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Instr. 8) Code (Instr. 8) P Dar 05/26/2021 P Dar 05/28/2021 P Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, or company (Month/Day/Year) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3) (Instr. 8)	Emmaus Life Sciences, In 3. Date of Earliest Transaction (105/26/2021 4. If Amendment, Date Original 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Par 05/26/2021 P Dar 05/27/2021 P Dar 05/28/2021 P Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, option any (Month/Day/Year) Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, option any (Month/Day/Year) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8) Table II - Derivative Securities Acquired, (a.g., puts, calls, warrants, option of (Instr. 8)	Emmaus Life Sciences, Inc. [EMN 0] (Middle) 3. Date of Earliest Transaction (Month/Da 05/26/2021 4. If Amendment, Date Original Filed(Month of Code (Month/Day/Year)) 4. If Amendment, Date Original Filed(Month of Code (Month/Day/Year)) 5. Table 1 - Non-Derivative Execution Date, if (Month/Day/Year) 6. Ode (Instr. 3) 6. Ode (Instr. 3) 7. Ode (Instr. 3) 7. Ode (Month/Day/Year) 7. Ode (Month/Day/Year) 8. Ode (Month/Day/Year) 9. Ode (Mont	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Year) 05/26/2021 4. If Amendment, Date Original Filed(Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Securities Date (Month/Day/Year) 4. Transaction Date (Month/Day/Year) 4. Transactio	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction (A) or Disposed of (Elnstr. 8) 4. Securities Acquired (A) or Disposed of (Date Carlier) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Date Execution Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (A) or Disposed of (Date Execution Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Date Execution Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (A) or Disposed of (Date Execution Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Date Execution Date (Month/Day/Year) 3. Transaction Date (A) or Disposed of (Date Execution Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Date Execution Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Date Execution Date (Month/Day/Year) 4. Date Expiration Date (Month/Day/Year) 4. Date Expiration Date (Month/Day/Year)	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Year) 05/26/2021 4. If Amendment, Date Original Filed(Month/Day/Year) 6 3. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 2A. Deemed (Instr. 8) (Instr. 3, 4 and 5) Date (Month/Day/Year) 2A. Deemed (Instr. 8) (Instr. 3, 4 and 5) P 2,700 A 1.53 24 Code V Amount (D) Price (Instr. 8) (Instr. 3, 4 and 5) P 2,700 A 1.53 24 Date (Bay Code (Instr. 8) (Instr. 8) (Instr. 8) (Instr. 8) Persons who respond to the contained in this form are the form displayed a current th/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficially and the form displayed a current th/Day/Year) (Instr. 8) (Instr. 8) Persons who respond to the contained in this form are the form displayed a current through the form displayed through through through the form displayed through through through through	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Year) 5. Cap Table I - Non-Derivative Securities Acquired, Disposed of (Disposed) 2. Transaction Date (Month/Day/Year) Date (Month/Day/Year) OS/26/2021 P 2,700 A 1.53 244,774 (Instr. 3, 4 and 5) OS/27/2021 P 2,000 A 1.58 246,774 OS/28/2021 P 3,900 A 1.57 250,674 OS/28/2021 P 3,900 A 1.57 250,674 OS/28/2021 P 3,900 A 1.58 250,674 OS/28/2021 P 3,900 A 1.57 250,674 OS/28/2021 Date Code V Amount of Disposed of (Disposed) OS/28/2021 P 2,000 A 1.58 246,774 (2) P 2,000 A 1.58 250,674 (3) OS/28/2021 P 3,900 A 1.57 250,674 (3) OS/28/2021 Date Code V Amount of Disposed of (Disposed) OS/28/2021 Date Code V Amount of Disposed of (Disposed) OS/28/2021 P 3,900 A 1.58 250,674 (3) OS/28/2021 Date Code V Amount of Disposed of Order (Code Contained in this form are not required this Disposed of Order (Code Contained in this form are not required (Code Contained (Code Contained (Code Contained (Code Contained (Code Code Contained (Code Contained (Co	Emmaus Life Sciences, Inc. [EMMA] Chiddle SulTE 800 S. 26/2021 SulTE 800 SulTE 800 SulTE 800 S. 26/2021 SulTE 800 SulTE 8	Emmaus Life Sciences, Inc. [EMMA] Check all apply Check all a	Emmaus Life Sciences, Inc. EMMA	Emmaus Life Sciences, Inc. [EMMA] Substitution Sciences Inc. [EMMA] Substitution Sciences Inc. [EMMA] Substitution Substitu	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			

LEE WILLIS C 21250 HAWTHORNE BLV SUITE 800 TORRANCE, CA 90503	TD. X		Vice Chairman & COO	
--	-------	--	---------------------	--

Signatures

Willis C. Lee	05/28/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.51 to \$1.59, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4
- (2) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.57 to \$1.59, inclusive.
- (3) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.50 to \$1.61, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.